A reactor erupts during a late-night pharmaceutical production run. Within moments, superheated solvent vapours meet airborne dust, ignition follows, and the blast tears through the building. Floors collapse. Lives are lost. In 2025, a tragedy of this magnitude unfolded at a Chemical plant in Telangana that caters to pharma, claiming nearly 40 workers and leaving dozens injured.  

This is not an isolated event. A global analysis of documented pharmaceutical process safety accidents between 1985 and 2019 recorded 73 major incidents and 108 fatalities. Nearly 90% of those deaths were caused by explosions, with the highest concentration of such events occurring in India and China. For an industry built on precision, these failures highlight a critical gap- the separation of Process Safety Management (PSM) from the Quality Management System (QMS). 

That is why process safety management in pharma can no longer be treated as a “chemical plant topic” that sits outside GMP (Good Manufacturing Practice) and quality. For modern facilities, Occupational Safety, GMP, and process safety are three sides of the same triangle, and a robust, well-structured pharma EHS audit program is what binds them together. 

In this blog, we’ll explore how pharma companies can use EHS audits and Process Safety Management (PSM) to meet regulatory and GMP  compliance requirements, without losing sight of productivity and cost.

Why Process Safety is a Core Pillar of GMP 

For years, pharmaceutical compliance models treated product quality systems and process safety systems as parallel tracks. One focused on batch integrity, documentation, and release controls. The other focused on fire protection, hazardous chemicals, and occupational risk. On paper, both looked complete. In practice, this artificial separation has proven dangerous. 

Modern pharmaceutical manufacturing now operates with: 

• Highly flammable and toxic solvents 
• Energetic chemical reactions 
• Fine combustible powders 
• High-pressure, high-temperature equipment 
• Tight cleanroom and HVAC dependencies 

When these realities intersect with GMP-controlled environments, process safety failures immediately become quality failures. 

• HVAC failures after thermal or fire events compromise pressure differentials, particulate control, and sterile boundaries far beyond the incident zone. 
• Solvent vapour excursions and dust clouds disrupt validated environmental conditions and increase the probability of cross-batch contamination. 
• Repeated containment breaches trigger regulatory scrutiny, forcing agencies to question not only safety governance but also data integrity and contamination control culture. 

At this point, safety is no longer an “EHS issue.” It becomes a core GMP risk driver.  

Global regulators no longer accept safety as a support function sitting outside the Quality Management System. They expect: 

• Change control processes to formally assess process safety impact 
• Deviation investigations to examine whether safety conditions contributed to quality failures 
• Validation strategies to account for abnormal operating conditions, not just ideal ones 
• Audit programs to test both operational discipline and accident-prevention systems together 

This expectation is anchored in internationally aligned guidance from World Health Organization, OSHA, PIC/S, and ECA Academy.

Regulatory Drivers: PSM, occupational Safety  and GMP Safety Compliance 

Pharmaceutical manufacturing is no longer governed by a single regulator, a single guideline, or a single safety philosophy. A modern pharma plant operates at the intersection of chemical safety, worker protection, environmental control, and product quality. Each of these domains is regulated independently, yet enforced collectively. This is precisely why process safety management in pharma, EHS governance, and GMP safety compliance can no longer be handled as separate compliance functions. 

Today, a pharma manufacturer is expected to demonstrate simultaneous compliance with multiple international and national frameworks, each reinforcing the same core expectation- Hazardous processes must be designed, operated, monitored, and audited with zero tolerance for uncontrolled risk.  

1.) Core regulations that shape pharma process safety 

Depending on product markets and plant footprint, pharmaceutical manufacturers must comply with multiple overlapping regulations that implicitly demand structured PSM maturity. 

• The Factories Act, 1948 & State Factory Rules:  Mandate hazard disclosure, medical surveillance, and worker protection for hazardous processes. Sections 41-B, 41-C, and 41-H explicitly require identification and control of process risks common to pharmaceutical synthesis. 

• The Manufacture, Storage, and Import of Hazardous Chemical (MSIHC) Rules, 1989: Often considered India’s closest equivalent to formal PSM requirements. These rules require Safety Reports, hazard studies such as HAZOP, and On-site Emergency Plans for facilities handling solvents and reactive chemicals above threshold quantities. 

• Petroleum Rules, 2002 & Static and Mobile Pressure Vessels (SMPV) Rules: Critical for solvent tank farms, hydrogen systems, and pressurized reactors. They demand engineered controls, inspections, and safe storage practices. 

• CDSCO & Revised Schedule M (GMP): Align Indian GMP with WHO and PIC/S expectations. Emphasizes Quality Risk Management and plant design controls, effectively making pharmaceutical plant safety a prerequisite for licensing. 

GMP safety compliance cannot exist without robust process safety and process safety is meaningless without regulatory enforceability. 

You may maintain flawless batch records and perfectly executed validation protocols. But if: 

• Your solvent recovery system lacks explosion isolation, or 
• Your dust extraction system is undersized or improperly grounded, 

then you are not considered compliant, regardless of your documentation strength. Regulators evaluate real-world risk, not just paperwork.

2.) How Process Safety Demonstrates GMP Control 

In a mature pharmaceutical environment, compliance is demonstrated through process safety capability, not periodic inspections. Regulators increasingly expect evidence that risk management in pharmaceutical manufacturing is: 

• Systematic: Built on formal hazard analysis in pharma industry operations such as HAZOP, dust hazard analysis, reaction calorimetry, and quantitative risk assessments, not operator experience or assumptions. 

• Documented and traceable: Fully embedded within GMP systems, with clear links to QMS records, deviation logs, CAPA actions, validation files, and Management of Change workflows, so every safeguard has evidence and accountability. 

• Dynamic and continuously updated: Reviewed whenever solvents, APIs, equipment, batch sizes, or operating parameters change, ensuring that new risks are identified before they reach the shop floor. 

During inspections, regulators now ask technical questions such as: 

• How were explosion risks evaluated for new solvents or intermediates? 
• What data supports dust explosibility controls in powder handling areas? 
• How are relief systems sized and verified? 
• How does Management of Change trigger safety reassessment? 
• Can the plant demonstrate engineered safeguards beyond SOPs? 

If answers rely on historical practice rather than structured analysis, compliance gaps become immediately visible. 

Because in modern pharma operations, process safety is no longer an add-on to GMP. It is the engineering foundation that keeps GMP conditions stable, defensible, and inspection-ready.

Building a PSM Framework That Actually Works in Pharma 

Standard PSM models such as OSHA’s 14-element structure provide a strong theoretical backbone, but in isolation they often feel disconnected from day-to-day pharmaceutical operations. In reality, process safety management in pharma becomes effective only when each PSM element is translated into the language of GMP, batch execution, equipment qualification, and controlled manufacturing environments. 

Below are the Core PSM elements adapted for pharma:  

• Process Safety Information (PSI) forms the technical foundation of the entire PSM system by documenting the physicochemical properties of APIs, intermediates, excipients, and solvents, including dust explosibility, ignition behavior, and thermal stability required for safe operating limits. 

• Process Hazard Analysis (PHA) translates chemical and mechanical risks into structured operational threat scenarios using techniques such as HAZOP and dust hazard analysis for reactors, dryers, granulators, and high-energy powder-handling areas. 

• Operating Procedures define the exact temperature, pressure, addition rates, inerting requirements, and cleaning methods that ensure processes remain within validated and intrinsically safe operating envelopes. 

• Training and Competency ensure that operators, maintenance personnel, and quality teams understand not only what tasks to perform but why specific controls exist and what escalation actions are required during abnormal conditions. 

• Management of Change (MoC) acts as the gatekeeper that prevents uncontrolled risk introduction by forcing safety, quality, engineering, and validation reviews whenever solvents, equipment, batch size, or process sequences change. 

• Mechanical Integrity preserves long-term process safety by enforcing inspection, testing, and maintenance of reactors, pressure relief systems, dust collectors, scrubbers, HVAC systems, and safety instrumentation before degradation becomes failure. 

• Incident Investigation and Learning converts fires, near-misses, and containment failures into structured knowledge through root cause analysis that feeds back into hazard reviews, SOP revisions, and training updates. 

These PSM elements cannot function as a parallel safety program operating outside quality governance. They must physically integrate with GMP safety compliance systems, including SOP control, validation protocols, deviation management, qualification records, and formal change control.

Digitalization: Making Process Safety Management Continuous in Pharma 

As pharmaceutical plants scale in complexity and regulatory scrutiny intensifies, traditional paper checklists, manual logs, and spreadsheet-based reviews are no longer sufficient to manage catastrophic risk. 

Modern facilities generate thousands of data points every day across reactors, solvent systems, dust handling equipment, utilities, and cleanroom infrastructure. When this information sits in silos, early warning signals are missed, and process safety management in pharma becomes reactive instead of preventive. 

Process safety today must operate in real time. Digital PSM platforms provide a centralized layer that integrates hazard studies, equipment integrity records, incident reports, training compliance, and Management of Change into one connected system. Instead of periodic reviews, safety performance is monitored continuously. 

For pharmaceutical plant safety, digitalization enables: 

• Real-time monitoring of critical assets such as reactors, solvent recovery units, scrubbers, and dust collectors 
• Automated tracking of mechanical integrity inspections and preventive maintenance 
• Direct linkage between deviations, CAPA, QMS, and safety safeguards 
• Predictive analytics on leading indicators like alarm bypasses, near-misses, or recurring minor leaks 
• Structured Management of Change workflows that automatically trigger safety and GMP impact reviews 
• Instant regulatory readiness through consolidated audit trails, hazard analyses, and training records 

This shift transforms safety from a periodic compliance activity into a live control system embedded inside daily operations. 

When digital tools support a mature PSM framework, risks are identified earlier, safeguards are verified faster, and failures are prevented before escalation. Safety stops being reactive. It becomes engineered, measurable, and continuously controlled, exactly what modern GMP environments demand.

Chola MS Risk Services Driving Safety, Compliance, and Competitive Advantage in Pharma 

In an industry where a single incident can trigger recalls, halt production, or invite global import restrictions, safety performance directly determines long-term credibility and growth. 

By aligning process safety management in pharma with structured EHS audits and GMP safety compliance, Chola MS Risk Services helps pharmaceutical manufacturers move beyond reactive compliance into proactive risk control. Our expertise spans hazard analysis in the pharma industry, advanced risk management in pharmaceutical manufacturing, and plant-wide pharma EHS audit frameworks designed to withstand both regulatory inspections and real-world operational stress. 

When safety, quality, and operations operate as a single integrated system, organizations achieve: 

• Lower probability of catastrophic fires, explosions, and toxic releases 
• Stronger protection for employees, surrounding communities, and brand reputation 
• Higher confidence during GMP and regulatory inspections 
• More stable, predictable, and cost-efficient manufacturing operations 

If your current environment still depends on surface-level audits and static checklists, the risk is already accumulating. 

-> Choose Chola MS Risk Services to upgrade your PSM and EHS audit framework for inspection-ready, incident-resilient pharma operations.

FAQs 

1. What is Process Safety Management in the pharma industry? 

Process safety management in pharma is a structured system used to prevent fires, explosions, toxic releases, and major accidents during pharmaceutical manufacturing. It focuses on controlling high-risk processes involving solvents, reactors, pressured systems, dust, and hazardous chemicals, going beyond routine workplace safety into catastrophic risk prevention. 

2. How is a pharma EHS audit different from a regular safety audit? 

A pharma EHS audit goes deeper than basic PPE checks. It evaluates: 

• Chemical and dust explosion risks 
• Process hazard studies (HAZOP, DHA) 
• GMP safety compliance 
• Emergency preparedness 
• Risk management in pharmaceutical manufacturing 

It connects worker safety with product quality and regulatory expectations. 

3. Is Process Safety Management mandatory for pharmaceutical companies? 

While PSM regulations like OSHA 1910.119 are legally mandatory in some regions, regulators worldwide expect equivalent controls under GMP safety compliance, IFC-EHS guidelines, and local factory laws. Any pharma unit handling flammable solvents, toxic reactions, or dust is expected to follow PSM principles. 

4. How does GMP safety compliance connect with pharmaceutical plant safety? 

GMP safety compliance ensures product quality, but pharmaceutical plant safety ensures the process itself is stable and controlled. A fire, explosion, or solvent release can shut down HVAC systems, contaminate sterile areas, damage validation status, and trigger regulatory bans. That’s why GMP and PSM must work together. 

5. What is included in hazard analysis in the pharma industry? 

Hazard analysis in pharma industry usually includes: 

• HAZOP and What-If studies for reactors and solvent systems 
• Dust hazard analysis for granulation and powder handling 
• Thermal stability and reaction calorimetry 
• Incompatibility and runaway reaction assessments 

These studies guide alarms, interlocks, SOP limits, and emergency planning.